Enoxaparin Dosing for Upper Extremity DVT
For treatment of upper extremity deep vein thrombosis, enoxaparin should be dosed at 1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg subcutaneously once daily, identical to lower extremity DVT treatment. 1
Treatment Regimen
The FDA-approved dosing for acute DVT treatment applies regardless of anatomic location (upper vs. lower extremity):
- 1 mg/kg subcutaneously every 12 hours (preferred for most patients), OR
- 1.5 mg/kg subcutaneously once daily 1
Both regimens are equally effective based on the FDA label, though the twice-daily dosing may provide more consistent anticoagulation. The once-daily regimen offers convenience but has not been as extensively studied in cancer patients 2.
Key Treatment Principles
Initiate warfarin concurrently (usually within 72 hours) and continue enoxaparin for a minimum of 5 days until INR reaches 2.0-3.0 for at least 24 hours 1. The average treatment duration is 7 days, though up to 17 days has been studied in clinical trials.
Special Populations
Renal Impairment
- Severe renal impairment (CrCl <30 mL/min): Reduce to 1 mg/kg subcutaneously once daily 1
- Moderate impairment (CrCl 30-50 mL/min): No dose adjustment needed, but monitor closely for bleeding 1
Cancer Patients
For cancer-associated upper extremity DVT (including catheter-related thrombosis), consider extended LMWH monotherapy without transition to warfarin 3, 2:
- Dalteparin: 200 units/kg once daily for 1 month, then 150 units/kg once daily (Category 1 recommendation) 3, 2
- Enoxaparin: 1 mg/kg every 12 hours or 1.5 mg/kg once daily for at least 3-6 months 3, 2
Continue anticoagulation for at least 3-6 months or as long as cancer or chemotherapy is ongoing 3, 4. In a prospective study of catheter-related upper extremity DVT in cancer patients, VTE recurrence occurred in 13.7% over 24 months, with prophylactic enoxaparin after initial treatment significantly reducing recurrence risk 5.
Critical Caveats
Do not switch between enoxaparin and unfractionated heparin during treatment—this increases bleeding risk 6, 7.
Weight extremes require attention: The optimal dose in patients >120 kg is unclear 7. For underweight patients (BMI <18.5 kg/m2), standard prophylactic doses appear safe, but therapeutic dosing data are limited 8.
Pregnancy considerations: Both 1 mg/kg twice daily and 1.5 mg/kg once daily regimens are effective and safe for DVT treatment during pregnancy 9. However, avoid multiple-dose vials containing benzyl alcohol in pregnant women when possible 1.
Monitor for thrombocytopenia: Check baseline and periodic platelet counts. If HIT is suspected, discontinue enoxaparin immediately 1.
The location of thrombosis (upper vs. lower extremity) does not alter the therapeutic dosing strategy—use the same weight-based regimens validated for all acute DVT treatment 1.